P. Klein

发表

Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management.

M. Grossbard, T. Shao, P. Klein, 2011, Clinical breast cancer.

Isolated sternal involvement in breast cancer: is it truly stage IV disease?

M. Citron, Yiwu Huang, A. Astrow, 2011, Clinical breast cancer.

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study

R. Snyder, A. Chan, B. Mookerjee, 2013, Investigational New Drugs.

Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2 + Metastatic Breast Cancer with of HER2

Joanne, J., M. Jahanzeb, 2002 .

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.

J. Mortimer, M. Jahanzeb, D. Irwin, 2002, The oncologist.

Abstract S1-02: PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy

J. Manola, B. Ramaswamy, A. Wolff, 2017 .

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial

B. Ramaswamy, C. Shapiro, J. Sparano, 2015, npj Breast Cancer.

Concordance between central and local lab IHC and FISH HER2 testing in a community-based trial of first-line trastuzumab plus a taxane in HER2+ metastatic breast cancer (MBC).

G. Lieberman, S. Anderson, J. Reddy, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of isolated leptomeningeal metastasis as the initial and sole site of recurrence in a patient with early-stage breast cancer

I. Preeshagul, P. Klein, C. Kakani, 2015, International Cancer Conference Journal.

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer

L. Esserman, H. Rugo, R. D'Agostino, 2017, JAMA.

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.

J. Manola, B. Ramaswamy, A. Wolff, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor – Positive , Human Epidermal Growth Factor Receptor 2 – Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy : Results of PrE 0102

J. Manola, B. Ramaswamy, A. Wolff, 2018 .

Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.

W. Symmans, S. Demaria, H. Yee, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Vitamin D and breast cancer.

M. Grossbard, T. Shao, P. Klein, 2012, The oncologist.

Clinical performance of the DigniCap system, a scalp hypothermia system, in preventing chemotherapy-induced alopecia.

H. Rugo, R. D'Agostino, M. Melisko, 2015 .

A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)

G. Sledge, Molin Wang, J. Sparano, 2017, Breast Cancer Research and Treatment.

Clinical significance of HER2-positive and triple-negative status in small (≤ 1 cm) node-negative breast cancer.

S. Boolbol, T. Shao, P. Klein, 2014, Clinical breast cancer.

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.

E. Winer, H. Burstein, P. Klein, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Plasmacytoma in the breast with axillary lymph node involvement: a case report.

S. Jagannath, D. Axelrod, A. Mazumder, 2006, Clinical breast cancer.

Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy.

D. Weaver, D. Krag, S. Feldman, 1999, Journal of the American College of Surgeons.

Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study

K. Boachie‐Adjei, W. Sikov, S. Boolbol, 2013, Breast Cancer Research and Treatment.

Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score® test

F. Baehner, M. Chadha, S. Boolbol, 2019, Breast Cancer Research and Treatment.

Paraneoplastic hypercalcemia in clear cell ovarian adenocarcinoma

F. Muggia, S. Lewin, K. Mittal, 2012, Ecancermedicalscience.

Breast Cancer Subtypes in Asian-Americans Differ According to Asian Ethnic Group

R. Simmons, M. Mazumdar, P. Christos, 2012, Journal of Immigrant and Minority Health.

An emerging generation of endocrine therapies in breast cancer: a clinical perspective

J. Sparano, P. Klein, A. Tiersten, 2023, npj Breast Cancer.

Anti-transcriptional intermediary factor-1γ antibody-positive dermatomyositis in a patient with triple-negative breast cancer treated with adjuvant capecitabine

G. Niedt, A. Kessler, A. Para, 2023, JAAD case reports.

The Association of Adjuvant Trastuzumab (Herceptin) with Radiation Recall Dermatitis: A Case Study

M. Spierer, P. Klein, Zaid S. Aljuboori, 2013 .

The Distinctive Role of Positron Emission Tomography/Computed Tomography in Breast Carcinoma with Brown Adipose Tissue 2‐Fluoro‐2‐Deoxy‐D‐Glucose Uptake

S. Heiba, Barbara Raphael, W. Cholewiński, 2005, The breast journal.

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study

R. Snyder, B. Mookerjee, M. Audeh, 2013, Investigational New Drugs.

Cediranib in Combination with Fulvestrant in Hormone-Sensitive Metastatic Breast Cancer: A Phase II Randomized Study.

R. Snyder, B. Mookerjee, M. Audeh, 2009 .